Ein Gun Song, MD
MOHS-Micrographic Surgery · Mill Creek, WANPI 1548536972
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,411,019 of the $4,536,884 with a category attached, or 75.2%. It is spread thinly across 32 manufacturers, the largest accounting for just 14.8%. 2025 is the largest year on record at $1,289,671, more than ten times the $41,145 reported in 2019. Among mohs-micrographic surgery clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 4,592 payments — averaging $988.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$673K
- Lilly USA, LLC$470K
- Sanofi$421K
- Pfizer$394K
- UCB, Inc.$393K
- Regeneron Healthcare Solutions, Inc.$325K
- plus $1.9M from 26 others
Across 242 payments — averaging $3991.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$235K
- AbbVie$157K
- Janssen Research & Development, LLC$154K
- Incyte Corporation$109K
- Amgen$106K
- Sun Pharmaceutical Industries Inc.$101K
- plus $103K from 4 others
What the payments were for
- Consulting fees$572,91313%
- Speaking & faculty fees$3,411,01975%
- Travel & lodging$467,31710%
- Food & beverage$85,2002%
- Education$4340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 697 | $673,079 |
| Lilly USA, LLC | 599 | $469,814 |
| Sanofi | 313 | $420,600 |
| Pfizer | 277 | $394,488 |
| UCB, Inc. | 487 | $393,433 |
| Regeneron Healthcare Solutions, Inc. | 321 | $324,662 |
| Incyte Corporation | 309 | $294,107 |
| E.r. Squibb & Sons, L.L.C. | 189 | $237,962 |
| Arcutis Biotherapeutics, Inc. | 263 | $231,210 |
| Johnson & Johnson | 239 | $224,442 |
| Amgen | 177 | $208,455 |
| Dermavant Sciences, Inc. | 157 | $172,152 |
| Sun Pharmaceutical Industries Inc. | 88 | $120,521 |
| Galderma Laboratories, L.p. | 113 | $84,713 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 90 | $80,199 |
| LEO Pharma Inc. | 58 | $56,340 |
| Janssen Scientific Affairs, LLC | 54 | $46,596 |
| Novartis | 101 | $38,363 |
| Organon | 23 | $28,481 |
| Boehringer Ingelheim | 6 | $13,556 |
| Eli Lilly | 12 | $11,462 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $5,218 |
| Almirall LLC | 1 | $3,250 |
| Eli Lilly Export S.A. Puerto Rico Branch | 3 | $2,491 |
| Kowa Pharmaceuticals America, Inc. | 1 | $750 |
| Sanofi-aventis U.S. LLC | 3 | $158 |
| Blueprint Medicines Corporation | 2 | $149 |
| Janssen Research & Development, LLC | 1 | $125 |
| Genentech USA, Inc. | 3 | $51 |
| Smith+Nephew | 1 | $23 |
| Prugen, Inc. Pharmaceuticals | 1 | $18 |
| Strata Skin Sciences, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,536,884 in reported general payments places this provider in the 95th percentile of 38 mohs-micrographic surgery providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 32 | $281,977 |
| Dupixent PenDupilumab | 57 | $252,361 |
| RinvoqUpadacitinib | 13 | $79,140 |
| OtezlaApremilast | 15 | $71,635 |
| Fluorouracil | 91 | $6,588 |
| Clobetasol Propionate | 160 | $6,559 |
| Tacrolimus | 36 | $3,295 |
| Ketoconazole | 133 | $1,843 |
| MethotrexateMethotrexate Sodium | 110 | $1,666 |
| Desonide | 26 | $1,374 |
| Doxycycline Hyclate | 39 | $1,264 |
| Dutasteride | 35 | $1,187 |
| Minoxidil | 104 | $1,065 |
| Clindamycin Phosphate | 24 | $945 |
| Mycophenolate Mofetil | 17 | $697 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $673,079 | $79,14013 claims |
| AmgenOtezla | $208,455 | $71,63515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 38 mohs-micrographic surgery providers in Washington.
Other mohs-micrographic surgery in Mill Creek
- Mustufa JafryMill Creek$4K
- Joy MakdisiMill Creek$671
- Dieter SchmidtMill Creek$551
- Jeremy PeckRichland$9K
- Marcus TanRenton$8K
- Mikel MuseVancouver$6K
- Jennifer ReichelSeattle$5K
- Kirk EcklundYakima$5K
- John NiaSpokane$5K
- Maureen MooneyUniversity Place$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.